Page 1

ventyx BIOSCIENCES Ventyx Biosciences Reports Third Quarter Financial Results and Provides Business Update November 17 , 2021 Wholly - owned pipeline with three clinical - stage programs targeting significant inflammatory and immunology disease markets Dosing initiated in a multiple - ascending dose ( MAD ) Phase 1 trial for VTX958 , an oral , selective tyrosine kinase type 2 ( TYK2 ) inhibitor , and a Phase 1 trial for VTX2735 , an oral Nod - like receptor protein 3 ( NLRP3 ) inhibitor Completed upsized initial public offering ( IPO ) of common stock , raising approximately $ 174.3 million in gross proceeds , including full exercise of underwriters ' option to purchase additional shares ENCINITAS , Calif . , Nov. 17 , 2021 ( GLOBE NEWSWIRE ) -- Ventyx Biosciences , Inc. ( Nasdaq : VTYX ) , ( " Ventyx " or the " Company " ) , a clinical - stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders , today announced financial results for the quarter ended September 30 , 2021 . " I am proud of our team's accomplishments as we work to build a leading immunology company that has three clinical stage programs , " said Raju Mohan , Chief Executive Officer of Ventyx . " By selectively modulating key immune targets we have been able to generate differentiated drug candidates that have the potential to improve and expand treatment options for the millions of patients suffering from inflammatory diseases and autoimmune disorders . We believe our capital position , supplemented by funds raised via our October IPO , provides us the opportunity to advance our clinical pipeline towards multiple important data catalysts . " Recent Corporate and Financial Highlights • On October 25 , 2021 , the Company announced the closing of its upsized initial public offering of 10,893,554 shares of its common stock , which includes the full exercise of the underwriters ' option to purchase 1,420,898 additional shares , at an initial public offering price of $ 16.00 per share . The aggregate net proceeds from the offering were approximately $ 158.8 million after deducting underwriting discounts , commissions and offering expenses . • Announced the appointment of Sheila Gujrathi , M.D. to the Board of Directors as Executive Chair and Jörn Drappa , M.D. , Ph.D. as Chief Medical Officer . The Company also expanded the Board of Directors with the appointment of William White as an independent director and appointed Luisa Salter - Cid , Ph.D. as Chair of the Scientific Advisory Board . • On September 9 , 2021 , the Company closed a $ 51.0 million Series B convertible preferred stock financing round . Business Update • VTX958 ( TYK2 Inhibitor ) : The Company's lead product candidate is VTX958 , an allosteric , orally bioavailable TYK2 inhibitor designed to selectively inhibit TYK2 without detectable inhibition of other JAK isoforms . We believe VTX958 has the potential to address a broad range of immune - mediated diseases , such as psoriasis , psoriatic arthritis , Crohn's disease and lupus , each of which represent substantial market opportunities . We completed the single - ascending dose portion of our Phase 1 trial for VTX958 and initiated dosing in the MAD trial in the fourth quarter of 2021 . • VTX002 ( S1P1R Modulator ) : We are developing VTX002 , an oral , selective Phase 2 - ready sphingosine 1 phosphate receptor 1 ( S1P1R ) modulator for ulcerative colitis ( UC ) . S1P1R is a clinically validated target . In our Phase 1 trial , VTX002 was well tolerated across all doses tested while producing dose - dependent reductions of circulating lymphocytes , a key biomarker of S1P1R modulator activity . Based on these data , we plan to initiate a Phase 2 randomized , placebo - controlled clinical trial in moderate - to - severe UC patients in the fourth quarter of 2021. We believe that this trial , along with an additional Phase 3 trial , may serve as the first of two pivotal trials required for registration . • VTX2735 ( NLRP3 Inhibitor ) : We are developing a comprehensive portfolio of NLRP3 inhibitors to address multiple indications driven by NLRP3 inflammasome activation . Our oral , selective and peripherally restricted NLRP3 inhibitor , VTX2735 , targets systemic inflammatory diseases , such as cardiovascular , hepatic , renal and rheumatologic diseases . We initiated dosing of VTX2735 in a Phase 1 trial in the fourth quarter of 2021 . • Preclinical Pipeline : In addition to VTX2735 , we are developing CNS - penetrant NLRP3 inhibitors and are currently evaluating candidates in the late stages of lead optimization . Based on preclinical and clinical evidence underscoring the pathogenic role of NLRP3 in neurodegenerative diseases , we believe CNS - penetrant NLRP3 inhibitors may have potential therapeutic utility for the treatment of Alzheimer's disease , Parkinson's disease , amyotrophic lateral sclerosis and multiple